Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 132

1.

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes.

Nene S, Gonczi L, Kurti Z, Morin I, Chavez K, Verdon C, Reinglas J, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

World J Gastroenterol. 2020 Feb 21;26(7):759-769. doi: 10.3748/wjg.v26.i7.759.

2.

Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.

Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

Dig Dis Sci. 2019 Dec 7. doi: 10.1007/s10620-019-05982-z. [Epub ahead of print]

PMID:
31813132
3.

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.

Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C.

J Can Assoc Gastroenterol. 2018 Dec;1(4):141-154. doi: 10.1093/jcag/gwy047. Epub 2018 Sep 14. Review.

4.

Erratum: A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?

Marcil V, Levy E, Amre D, Bitton A, Sant'Anna AMGA, Szilagy A, Sinnett D, Seidman EG.

Inflamm Bowel Dis. 2020 Jan 1;26(1):160. doi: 10.1093/ibd/izz275. No abstract available.

PMID:
31746991
5.

Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary.

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J.

J Can Assoc Gastroenterol. 2019 Dec;2(4):149-152. doi: 10.1093/jcag/gwy069. Epub 2019 Feb 1.

6.

Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data.

Romagnoni A, J├ęgou S, Van Steen K, Wainrib G, Hugot JP; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC).

Sci Rep. 2019 Jul 17;9(1):10351. doi: 10.1038/s41598-019-46649-z.

7.

Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis.

Hart L, Chavannes M, Kherad O, Maedler C, Mourad N, Marcus V, Afif W, Bitton A, Lakatos PL, Brassard P, Bessissow T.

J Crohns Colitis. 2020 Jan 1;14(1):46-52. doi: 10.1093/ecco-jcc/jjz107.

PMID:
31314884
8.

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada.

Rose KL, Sherman PM, Cooke-Lauder J, Mawani M, Benchimol EI, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S81-S91. doi: 10.1093/jcag/gwy057. Epub 2018 Nov 2.

9.

The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.

Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.

10.

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.

Nguyen GC, Targownik LE, Singh H, Benchimol EI, Bitton A, Murthy SK, Bernstein CN, Lee K, Cooke-Lauder J, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2.

11.

The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.

Carroll MW, Kuenzig ME, Mack DR, Otley AR, Griffiths AM, Kaplan GG, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.

12.

The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life.

Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S42-S48. doi: 10.1093/jcag/gwy048. Epub 2018 Nov 2.

13.

The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.

Kuenzig ME, Lee L, El-Matary W, Weizman AV, Benchimol EI, Kaplan GG, Nguyen GC, Bernstein CN, Bitton A, Lee K, Cooke-Lauder J, Murthy SK.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2.

14.

The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.

15.

The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.

Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2.

16.

The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada.

Benchimol EI, Bernstein CN, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Siddiq S, Windsor JW, Carroll MW, Coward S, El-Matary W, Griffiths AM, Jones JL, Kuenzig ME, Lee L, Mack DR, Mawani M, Otley AR, Singh H, Targownik LE, Weizman AV, Kaplan GG.

J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S1-S5. doi: 10.1093/jcag/gwy052. Epub 2018 Nov 2.

17.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

J Can Assoc Gastroenterol. 2019 Aug;2(3):e1-e34. doi: 10.1093/jcag/gwz019. Epub 2018 Jul 10.

18.

Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease.

Turpin W, Espin-Garcia O, Bedrani L, Madsen K, Meddings JB, Raygoza Garay JA, Silverberg MS, Smith MI, Griffiths AM, Moayyedi P, Marshall JK, Mack D, Seidman EG, Ropeleski M, Feagan BG, Jacobson K, Turner D, Walters T, Paterson AD; CCC GEM Project Research Consortium, Xu W, Croitoru K.

Inflamm Bowel Dis. 2019 Oct 18;25(11):1796-1804. doi: 10.1093/ibd/izz116.

PMID:
31251335
19.

High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.

Singh K, Al Khoury A, Kurti Z, Gonczi L, Reinglas J, Verdon C, Kohen R, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL.

J Crohns Colitis. 2019 Sep 27;13(10):1343-1350. doi: 10.1093/ecco-jcc/jjz066.

PMID:
30918959
20.

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease.

Chao CY, Lemieux C, Restellini S, Afif W, Bitton A, Lakatos PL, Wild G, Bessissow T.

Saudi J Gastroenterol. 2019 May-Jun;25(3):159-166. doi: 10.4103/sjg.SJG_566_18.

Supplemental Content

Loading ...
Support Center